- Home
- IMMX vs ALGS Comparison
IMMX vs ALGS Comparison
Compare IMMX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ALGS
- Stock Information
- Founded
- IMMX 2014
- ALGS 2018
- Country
- IMMX United States
- ALGS United States
- Employees
- IMMX N/A
- ALGS N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- ALGS Health Care
- Exchange
- IMMX Nasdaq
- ALGS Nasdaq
- Market Cap
- IMMX 65.5M
- ALGS 53.0M
- IPO Year
- IMMX 2021
- ALGS 2020
- Fundamental
- Price
- IMMX $2.47
- ALGS $9.86
- Analyst Decision
- IMMX Strong Buy
- ALGS Strong Buy
- Analyst Count
- IMMX 1
- ALGS 2
- Target Price
- IMMX $8.00
- ALGS $60.00
- AVG Volume (30 Days)
- IMMX 221.4K
- ALGS 72.0K
- Earning Date
- IMMX 11-11-2025
- ALGS 11-05-2025
- Dividend Yield
- IMMX N/A
- ALGS N/A
- EPS Growth
- IMMX N/A
- ALGS N/A
- EPS
- IMMX N/A
- ALGS N/A
- Revenue
- IMMX N/A
- ALGS $3,174,000.00
- Revenue This Year
- IMMX N/A
- ALGS N/A
- Revenue Next Year
- IMMX N/A
- ALGS N/A
- P/E Ratio
- IMMX N/A
- ALGS N/A
- Revenue Growth
- IMMX N/A
- ALGS N/A
- 52 Week Low
- IMMX $1.34
- ALGS $3.76
- 52 Week High
- IMMX $3.20
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- IMMX 67.32
- ALGS 50.65
- Support Level
- IMMX $1.94
- ALGS $9.60
- Resistance Level
- IMMX $2.13
- ALGS $10.70
- Average True Range (ATR)
- IMMX 0.16
- ALGS 0.76
- MACD
- IMMX 0.05
- ALGS -0.02
- Stochastic Oscillator
- IMMX 99.45
- ALGS 41.30
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.